Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Improved Assays in Pain Research Using Native Neurons

Published: Saturday, May 10, 2014
Last Updated: Saturday, May 10, 2014
Bookmark and Share
Cellectricon and Neusentis to present a webinar on May 16, from 11am EDT.

Cellectricon will co-host a webinar with Neusentis, describing the use of native cells to develop an assay with improved physiological relevance over traditional approaches in pain drug discovery research.

Entitled ‘Development of Cell-Based Assays for Pain Drug Discovery Using Native Sensory Neurons’, the webinar will take place on May 16 at 11am EDT; researchers can register at www.cellecticon.com/events.

Cellectricon is creating model systems with native neurons for registering changes in neural activity - both at the cellular and network level - using its Cellaxess® Elektra discovery platform, and Neusentis is a Pfizer Research Unit focusing on pain and sensory disorders.

Webinar participants will gain further understanding of the underlying mechanisms causing chronic pain, and learn more about phenotypic screening approaches in pain research and the use of compound profiling to advance research in the CNS and pain therapeutic fields.

Presentations from Dr Darren Cawkill, Associate Research Fellow at Neusentis, and Dr Paul Karila, VP Discovery Services, Cellectricon, will cover the results from their assay development work. Dr Cawkill will go on to present data from an additional phenotypic screening case study, which describes the progress towards high-throughput compatible assays using both primary rat neuronal cultures and human stem cell-derived sensory neurons. There will also be a discussion on how such phenotypic screening assays could be integrated into drug discovery programs.

Aimed at R&D scientists working in drug discovery, neuroscience, translational science, high content biology, electrophysiology and ion channel research, ‘Development of Cell-Based Assays for Pain Drug Discovery Using Native Sensory Neurons’, will take place at 11am EDT on May 16.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellectricon Establishes Scientific Advisory Board to Enhance Its Pain and CNS Discovery Services
The company, a leading provider of advanced cell-based discovery services, has appointed Dr Edwin Johnson, Director of The Stockholm Brain Institute, as the first member of its new Scientific Advisory Board.
Thursday, July 09, 2015
UCL’s Novel Approach to Research in Biologically-Relevant Models
Cellectricon and UCL unite to present a webinar, March 27, 11am-12pm EDT.
Wednesday, March 19, 2014
Cellectricon Announces Project Grant Winners
The grant was awarded for project proposals utilizing Cellectricon’s Cellaxess ACE technology for the delivery of non-genetic material to adherent cells and cultures.
Thursday, September 19, 2013
Presenting Phenotypic Screening Strategies for Chronic Pain Research
Cellectricon explores novel phenotypic assay designs in a webinar, 5 September, 11am-12pm (EDT).
Wednesday, August 21, 2013
Cellectricon Launches Grant to Fund Electroporation-based Research
New Cellaxess® Project Grant supports advanced research projects.
Wednesday, July 10, 2013
Identifying Unknown Modulators of Pain with New Phenotypic Assays
Cellectricon presentation: SMi Pain Therapeutics conference, 20 May, 11am.
Tuesday, May 14, 2013
Dr. Paul Karila appointed Head of Discovery Services at Cellectricon AB
Discovery services will be based on automated cellular electric field manipulation for novel screening applications.
Wednesday, June 13, 2012
Cellectricon Receives Milestone Order for Cellaxess®HT High Throughput RNAi Screening System
Cellectricon receives the largest single order to deliver three Cellaxess®HT systems to a leading US biotech firm.
Friday, November 14, 2008
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Battery Component Found to Harm Key Soil Microorganism
The material at the heart of the lithium ion batteries that power electric vehicles, laptop computers and smartphones has been shown to impair a key soil bacterium, according to new research.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Validating the Accuracy of CRISPR-Cas9
IBS Researchers create multiplex Digenome-seq to find errors in CRISPR-Cas9 processes.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!